Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 New treatment options for patients with newly diagnosed multiple myeloma

From: Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting

Author (year)

Study

Setting

Experimental arm

Control arm

N

Age (median)

Follow-up (median)

PFS

MRD negativity (10− 5)

Mai et al. (2024)

GMMG-HD7

NDMM transplant eligible

IsaVRd

VRd

660

59.5

48.0

HR = 0.70 (95% CI: 0.52–0.95)

66.2% vs. 47.7%, p < 0.001

OR = 2.13 (95% CI: 1.56–2.92)

Zweegman et al. (2024)

CEPHEUS

NDMM transplant ineligible

DaraVRd

VRd

395

70.0

58.7

54 m PFS: 68.1% vs. 49.5%, p < 0.001

HR = 0.57 (95% CI: 0.41–0.79)

60.9% vs. 39.4%, p < 0.001

OR = 2.37 (95% CI: 1.58–3.55)

Sustained MRD neg ≥ 12 months

48.7% vs. 26.3%, p < 0.001

  1. NDMM: newly diagnosed multiple myeloma; Dara: daratumumab; Isa: isatuximab; V: bortezomib; R: lenalidomide; d: dexamethasone; HR: hazard ratio; OR: odds ratio; PFS: progression-free survival; CI: confidence interval; MRD: minimal residual disease
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us